A citation-based method for searching scientific literature

Mingye Feng, Wen Jiang, Betty Y S Kim, Cheng Cheng Zhang, Yang-Xin Fu, Irving L Weissman. Nat Rev Cancer 2019
Times Cited: 246







List of co-cited articles
1207 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Ranjana Advani, Ian Flinn, Leslie Popplewell, Andres Forero, Nancy L Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann LaCasce, Graham P Collins,[...]. N Engl J Med 2018
489
28

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Ravindra Majeti, Mark P Chao, Ash A Alizadeh, Wendy W Pang, Siddhartha Jaiswal, Kenneth D Gibbs, Nico van Rooijen, Irving L Weissman. Cell 2009
976
22

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Mark P Chao, Ash A Alizadeh, Chad Tang, June H Myklebust, Bindu Varghese, Saar Gill, Max Jan, Adriel C Cha, Charles K Chan, Brent T Tan,[...]. Cell 2010
667
22

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Stephen B Willingham, Jens-Peter Volkmer, Andrew J Gentles, Debashis Sahoo, Piero Dalerba, Siddhartha S Mitra, Jian Wang, Humberto Contreras-Trujillo, Robin Martin, Justin D Cohen,[...]. Proc Natl Acad Sci U S A 2012
848
22

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Sydney R Gordon, Roy L Maute, Ben W Dulken, Gregor Hutter, Benson M George, Melissa N McCracken, Rohit Gupta, Jonathan M Tsai, Rahul Sinha, Daniel Corey,[...]. Nature 2017
919
21

Targeting macrophages: therapeutic approaches in cancer.
Luca Cassetta, Jeffrey W Pollard. Nat Rev Drug Discov 2018
640
18

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.
Siddhartha Jaiswal, Catriona H M Jamieson, Wendy W Pang, Christopher Y Park, Mark P Chao, Ravindra Majeti, David Traver, Nico van Rooijen, Irving L Weissman. Cell 2009
916
18

CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
Xiaojuan Liu, Yang Pu, Kyle Cron, Liufu Deng, Justin Kline, William A Frazier, Hairong Xu, Hua Peng, Yang-Xin Fu, Meng Michelle Xu. Nat Med 2015
399
18

Tumour-associated macrophages as treatment targets in oncology.
Alberto Mantovani, Federica Marchesi, Alberto Malesci, Luigi Laghi, Paola Allavena. Nat Rev Clin Oncol 2017
17

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Amira A Barkal, Rachel E Brewer, Maxim Markovic, Mark Kowarsky, Sammy A Barkal, Balyn W Zaro, Venkatesh Krishnan, Jason Hatakeyama, Oliver Dorigo, Layla J Barkal,[...]. Nature 2019
358
16

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Nan Guo Ring, Dietmar Herndler-Brandstetter, Kipp Weiskopf, Liang Shan, Jens-Peter Volkmer, Benson M George, Melanie Lietzenmayer, Kelly M McKenna, Tejaswitha J Naik, Aaron McCarty,[...]. Proc Natl Acad Sci U S A 2017
152
14

Tumor-associated macrophages: from mechanisms to therapy.
Roy Noy, Jeffrey W Pollard. Immunity 2014
13

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Hanke L Matlung, Katka Szilagyi, Neil A Barclay, Timo K van den Berg. Immunol Rev 2017
227
13

Macrophages as regulators of tumour immunity and immunotherapy.
David G DeNardo, Brian Ruffell. Nat Rev Immunol 2019
621
13

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Sharareh Gholamin, Siddhartha S Mitra, Abdullah H Feroze, Jie Liu, Suzana A Kahn, Michael Zhang, Rogelio Esparza, Chase Richard, Vijay Ramaswamy, Marc Remke,[...]. Sci Transl Med 2017
189
13

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.
Kipp Weiskopf, Aaron M Ring, Chia Chi M Ho, Jens-Peter Volkmer, Aron M Levin, Anne Kathrin Volkmer, Engin Ozkan, Nathaniel B Fernhoff, Matt van de Rijn, Irving L Weissman,[...]. Science 2013
285
12

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Branimir I Sikic, Nehal Lakhani, Amita Patnaik, Sumit A Shah, Sreenivasa R Chandana, Drew Rasco, A Dimitrios Colevas, Timothy O'Rourke, Sujata Narayanan, Kyriakos Papadopoulos,[...]. J Clin Oncol 2019
203
12

Role of CD47 as a marker of self on red blood cells.
P A Oldenborg, A Zheleznyak, Y F Fang, C F Lagenaur, H D Gresham, F P Lindberg. Science 2000
12

CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
Stephanie M Pyonteck, Leila Akkari, Alberto J Schuhmacher, Robert L Bowman, Lisa Sevenich, Daniela F Quail, Oakley C Olson, Marsha L Quick, Jason T Huse, Virginia Teijeiro,[...]. Nat Med 2013
12

Human chimeric antigen receptor macrophages for cancer immunotherapy.
Michael Klichinsky, Marco Ruella, Olga Shestova, Xueqing Maggie Lu, Andrew Best, Martha Zeeman, Maggie Schmierer, Konrad Gabrusiewicz, Nicholas R Anderson, Nicholas E Petty,[...]. Nat Biotechnol 2020
288
12

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Amira A Barkal, Kipp Weiskopf, Kevin S Kao, Sydney R Gordon, Benyamin Rosental, Ying Y Yiu, Benson M George, Maxim Markovic, Nan G Ring, Jonathan M Tsai,[...]. Nat Immunol 2018
199
12

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
Diane Tseng, Jens-Peter Volkmer, Stephen B Willingham, Humberto Contreras-Trujillo, John W Fathman, Nathaniel B Fernhoff, Jun Seita, Matthew A Inlay, Kipp Weiskopf, Masanori Miyanishi,[...]. Proc Natl Acad Sci U S A 2013
346
11


Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Timothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, Brian A Belt, Roheena Z Panni, Brian M Cusworth, Adetunji T Toriola, Rebecca K Nieman, Lori A Worley, Motoyo Yano,[...]. Lancet Oncol 2016
390
11

The cellular and molecular origin of tumor-associated macrophages.
Ruth A Franklin, Will Liao, Abira Sarkar, Myoungjoo V Kim, Michael R Bivona, Kang Liu, Eric G Pamer, Ming O Li. Science 2014
774
11

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Gregory L Beatty, Elena G Chiorean, Matthew P Fishman, Babak Saboury, Ursina R Teitelbaum, Weijing Sun, Richard D Huhn, Wenru Song, Dongguang Li, Leslie L Sharp,[...]. Science 2011
11


Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.
Mark P Chao, Siddhartha Jaiswal, Rachel Weissman-Tsukamoto, Ash A Alizadeh, Andrew J Gentles, Jens Volkmer, Kipp Weiskopf, Stephen B Willingham, Tal Raveh, Christopher Y Park,[...]. Sci Transl Med 2010
418
10

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Carola H Ries, Michael A Cannarile, Sabine Hoves, Jörg Benz, Katharina Wartha, Valeria Runza, Flora Rey-Giraud, Leon P Pradel, Friedrich Feuerhake, Irina Klaman,[...]. Cancer Cell 2014
791
10

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Penka S Petrova, Natasja Nielsen Viller, Mark Wong, Xinli Pang, Gloria H Y Lin, Karen Dodge, Vien Chai, Hui Chen, Vivian Lee, Violetta House,[...]. Clin Cancer Res 2017
155
10

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Jie Liu, Lijuan Wang, Feifei Zhao, Serena Tseng, Cyndhavi Narayanan, Lei Shura, Stephen Willingham, Maureen Howard, Susan Prohaska, Jens Volkmer,[...]. PLoS One 2015
267
9

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
Kipp Weiskopf, Nadine S Jahchan, Peter J Schnorr, Sandra Cristea, Aaron M Ring, Roy L Maute, Anne K Volkmer, Jens-Peter Volkmer, Jie Liu, Jing Shan Lim,[...]. J Clin Invest 2016
212
9

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
Meike E W Logtenberg, J H Marco Jansen, Matthijs Raaben, Mireille Toebes, Katka Franke, Arianne M Brandsma, Hanke L Matlung, Astrid Fauster, Raquel Gomez-Eerland, Noor A M Bakker,[...]. Nat Med 2019
83
10

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Yu Zhu, Brett L Knolhoff, Melissa A Meyer, Timothy M Nywening, Brian L West, Jingqin Luo, Andrea Wang-Gillam, S Peter Goedegebuure, David C Linehan, David G DeNardo. Cancer Res 2014
722
9

Role of macrophage targeting in the antitumor activity of trabectedin.
Giovanni Germano, Roberta Frapolli, Cristina Belgiovine, Achille Anselmo, Samantha Pesce, Manuela Liguori, Eugenio Erba, Sarah Uboldi, Massimo Zucchetti, Fabio Pasqualini,[...]. Cancer Cell 2013
538
9

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
Bin-Zhi Qian, Jiufeng Li, Hui Zhang, Takanori Kitamura, Jinghang Zhang, Liam R Campion, Elizabeth A Kaiser, Linda A Snyder, Jeffrey W Pollard. Nature 2011
9

Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species.
Rapolas Zilionis, Camilla Engblom, Christina Pfirschke, Virginia Savova, David Zemmour, Hatice D Saatcioglu, Indira Krishnan, Giorgia Maroni, Claire V Meyerovitz, Clara M Kerwin,[...]. Immunity 2019
444
9

The CD47-SIRPα Immune Checkpoint.
Meike E W Logtenberg, Ferenc A Scheeren, Ton N Schumacher. Immunity 2020
86
10

Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Jonathan T Sockolosky, Michael Dougan, Jessica R Ingram, Chia Chi M Ho, Monique J Kauke, Steven C Almo, Hidde L Ploegh, K Christopher Garcia. Proc Natl Acad Sci U S A 2016
192
9

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
André Veillette, Jun Chen. Trends Immunol 2018
172
8


Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.
Laura Bonapace, Marie-May Coissieux, Jeffrey Wyckoff, Kirsten D Mertz, Zsuzsanna Varga, Tobias Junt, Mohamed Bentires-Alj. Nature 2014
410
8

Neutrophil diversity and plasticity in tumour progression and therapy.
Sebastien Jaillon, Andrea Ponzetta, Diletta Di Mitri, Angela Santoni, Raffaella Bonecchi, Alberto Mantovani. Nat Rev Cancer 2020
202
8

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
8

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.
Hanke L Matlung, Liane Babes, Xi Wen Zhao, Michel van Houdt, Louise W Treffers, Dieke J van Rees, Katka Franke, Karin Schornagel, Paul Verkuijlen, Hans Janssen,[...]. Cell Rep 2018
148
8

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Jennifer L Guerriero, Alaba Sotayo, Holly E Ponichtera, Jessica A Castrillon, Alexandra L Pourzia, Sara Schad, Shawn F Johnson, Ruben D Carrasco, Suzan Lazo, Roderick T Bronson,[...]. Nature 2017
294
8

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
Alberto Mantovani, Silvano Sozzani, Massimo Locati, Paola Allavena, Antonio Sica. Trends Immunol 2002
8

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.
Yu Zhu, John M Herndon, Dorothy K Sojka, Ki-Wook Kim, Brett L Knolhoff, Chong Zuo, Darren R Cullinan, Jingqin Luo, Audrey R Bearden, Kory J Lavine,[...]. Immunity 2017
264
8

Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.
Mingye Feng, James Y Chen, Rachel Weissman-Tsukamoto, Jens-Peter Volkmer, Po Yi Ho, Kelly M McKenna, Samuel Cheshier, Michael Zhang, Nan Guo, Phung Gip,[...]. Proc Natl Acad Sci U S A 2015
151
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.